-

Joel Pecoy Joins Barings to Lead U.S. Real Estate Debt Asset Management

CHARLOTTE, N.C.--(BUSINESS WIRE)--Barings, one of the world’s largest diversified real estate investment managers, announced today that industry veteran Joel Pecoy has joined Barings to lead U.S. Real Estate Debt Asset Management, effective immediately. In his new role, Pecoy will be responsible for managing an approximately $25 billion real estate debt portfolio covering nearly 380 assets in the U.S. He will join the U.S. Real Estate Debt Investment Committee and oversee a team of 12 asset managers and servicers, reporting to Nasir Alamgir, Head of U.S. and European Real Estate Debt.

“We are thrilled to welcome Joel to our team and to build on our strong momentum as we navigate an evolving real estate landscape and seek to unlock value for our investors across the risk spectrum,” said Alamgir. “We believe Joel’s proven track record of managing loans through multiple economic cycles, his leadership skillset, and team-based approach to investing will further enhance our capabilities as we continue to grow our platform over the long term.”

Pecoy brings over 25 years of real estate investing experience to the team, most recently serving as Head of Real Estate Debt Asset Management at Ares. Prior to Ares, Pecoy served as Head of Debt Asset Management at UC Funds and as Finance and Acquisitions Manager at Colony Hills Capital. He has a B.A. in Business from the University of Massachusetts and was a Petty Officer Second Class in the U.S. Navy.

“I’m excited to join a deep bench of senior leaders and a platform that I have long admired, with a strong growth trajectory, broad direct origination capabilities, and deep credit expertise,” said Pecoy. “I look forward to further enhancing Barings’ asset management capabilities and to deepening our close partnership with origination, portfolio management, underwriting, and servicing teams as the platform continues to expand.”

About Barings

Barings is a $431+ billion* global asset management firm that partners with institutional, insurance, and intermediary clients, and supports leading businesses with flexible financing solutions. The firm, a subsidiary of MassMutual, seeks to deliver excess returns by leveraging its global scale and capabilities across public and private markets in fixed income, real assets and capital solutions.

*Assets under management as of September 30, 2024

Barings


Release Versions

More News From Barings

Barings Appoints Ankit Aggarwal as Head of Global CLO Issuance and Capital Markets

CHARLOTTE, N.C.--(BUSINESS WIRE)--Barings, one of the world’s leading alternative investment managers, announced today that Ankit Aggarwal has joined the firm as Head of Global CLO Issuance and Capital Markets to further scale Barings’ CLO platform. Based in New York, he will report to Adrienne Butler, Head of Global CLOs. In this newly created role, Aggarwal will lead Barings' global CLO issuance platform and capital markets strategy, helping to accelerate the continued growth of the $55 billi...

Barings Global Short Duration High Yield Fund Announces September 2026 Monthly Distribution of $0.1223 per Share

CHARLOTTE, N.C.--(BUSINESS WIRE)--The Barings Global Short Duration High Yield Fund (the “Fund”) (NYSE: BGH) announced its monthly dividend for September 2026 of $0.1223 per share, payable on October 1, 2026. Based on the Fund’s August 31, 2026 share price of $14.24 per share, the dividend represents an annualized yield of 10.31% per share. Based on current projections through the payable date, the Fund expects that this dividend will be comprised of net investment income. In addition, the Fund...

Barings Provides Senior Secured Financing to Soleus Capital to Expand Healthcare Credit and Royalty Platform

CHARLOTTE, N.C.--(BUSINESS WIRE)--Barings, one of the world's leading investment managers, today announced that it has provided a senior secured financing facility to Soleus Capital ("Soleus"), an investment firm investing across healthcare with a focus on the innovative areas of life sciences, including biopharmaceuticals, medical devices, life science tools and diagnostics. The financing, which is secured by a diversified portfolio of established royalties generated from commercial-stage phar...
Back to Newsroom